August 7, 2024 01:19 AM EDT
People
R&D

Pre­ci­gen lays off staff, paus­es mul­ti­ple CAR-T pro­grams and all pre­clin­i­cal work and aims for $30M of­fer­ing

Kyle LaHucik

Senior Reporter

Mary­land biotech Pre­ci­gen said it will lay off more than 20% of its work­force, pause mul­ti­ple CAR-T clin­i­cal pro­grams, halt all …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

As­traZeneca, Gilead de­tail TROP2 ADC da­ta in lung can­cer as they search for new ways for­ward

Lil­ly again hires from with­in for CFO post, el­e­vat­ing 23-year com­pa­ny vet­er­an

Mer­ck, Dai­ichi Sankyo de­tail Phase 2 ADC re­sults in small cell lung can­cer, bis­pe­cif­ic com­bo strat­e­gy

Terns’ oral GLP-1 pass­es Phase 1 test with promis­ing weight loss af­ter one month

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

A service from the Financial Times